在B细胞淋巴瘤中,SETD1B突变赋予了细胞灭亡耐药性和BCL2独立性
Ana Portelinha1, Shenqiu Wang1, Sara Parsa1
1Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center , New York, NY, USA.
The Journal of experimental medicine
|September 5, 2024
概括
在卵泡淋巴瘤 (FL) 和扩散大B细胞淋巴瘤 (DLBCL) 中,SETD1B突变会导致对BCL2抑制剂如Venetoclax的耐药性. 向KDM5脱甲基酶可以恢复这些耐药淋巴瘤的药物敏感性.
科学领域:
- 血液学 血液学 血液学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 在瘤学瘤学.
背景情况:
- 毛囊性淋巴瘤 (FL) 通常由t(14;18) 转位启动,激活BCL2.
- 矛盾的是,尽管BCL2激活,但FL患者对BCL2抑制剂Venetoclax没有反应.
研究的目的:
- 研究SETD1B (KMT2G) 突变在淋巴瘤对BCL2抑制剂耐药性的作用.
- 探索SETD1B作为瘤抑制剂及其与KMT2D在淋巴瘤发展中的合作.
- 确定治疗策略,以克服SETD1B缺陷淋巴瘤中Venetoclax耐药性的治疗方法.
主要方法:
- 在FL和DLBCL患者样本中分析SETD1B突变和缺失.
- 评估SETD1B缺乏细胞中Venetoclax和MCL-1抑制剂的耐药性.
- 在体内淋巴瘤发育研究涉及SETD1B和KMT2D损失.
- 调查SETD1B在调节前性BCL2家族蛋白质中的作用.
- 对KDM5脱甲基酶抑制剂与Venetoclax结合的评估.
主要成果:
- 在7%的FL和16%的DLBCL中发生SETD1B突变/删除,从而产生对Venetoclax和MCL-1抑制剂的耐药性.
- SETD1B作为瘤抑制剂起作用,在淋巴瘤发育中与KMT2D损失合作.
- 在人类淋巴瘤中,SETD1B的损失通常与KMT2D的损失相吻合.
- SETD1B对于像BIM和BIK这样的亲细胞突变的BCL2家族蛋白质的表达至关重要.
- KDM5脱甲基酶抑制剂恢复BIM和BIK的表达,并在SETD1B缺陷淋巴瘤中与Venetoclax进行协同作用.
结论:
- 在淋巴瘤中,SETD1B是细胞死亡途径的关键表观遗传调节者.
- SETD1B 缺乏是对BCL2 抑制剂耐药性的关键机制.
- 抑制KDM5脱甲基酶提供了一种有前途的策略,以增强抗性淋巴瘤中的Venetoclax敏感性.
相关概念视频
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Extrinsic Apoptotic Pathway
6.3K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.3K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
B Cell Activation and Differentiation
1.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.7K


